❌

Reading view

Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial

Nature Medicine, Published online: 11 September 2026; doi:10.1038/s41591-026-04642-w

In the randomized phase 2 ImmunoPRISM trial, patients with high-risk smoldering multiple myeloma (MM) showed higher rates of complete clinical responses in response to treatment with teclistamab compared with lenalidomide–dexamethasone, although longer follow-up is required to determine durable prevention of progression to MM.
  •  

Commensal <i>Nakaseomyces glabratus</i> migrates into prostate tumors to accelerate cancer progression

Nature Cancer, Published online: 09 September 2026; doi:10.1038/s43018-026-01229-9

Lai et al. show that Nakaseomyces glabratus is enriched in fecal and tumor samples of patients with castration-resistant prostate cancer and that administration of the fungus accelerates cancer progression in prostate cancer-bearing castrated mice.
  •  

Lipotoxicity-induced ER-mitochondrial hypercoupling activates the mtDNA-cGAS-STING-NF-κB axis to drive follicular arrest in metabolically compromised PCOS

Cell Death Discovery, Published online: 08 September 2026; doi:10.1038/s41420-026-03339-w

Lipotoxicity-induced ER-mitochondrial hypercoupling activates the mtDNA-cGAS-STING-NF-κB axis to drive follicular arrest in metabolically compromised PCOS
  •  

Pan-neurodegeneration proteomics reveals disease subtypes and molecular signatures

A pan-neurodegeneration atlas built from multilayer, deep proteomics of 2,279 brain samples across 6 major diseases integrates whole proteome, detergent-insoluble proteome, and posttranslational modifications to enable intra- and inter-disease comparisons to reveal disease-specific subtypes and dysregulated pathways, while identifying shared changes such as GPNMB upregulation and NPTX2 downregulation.
  •  
❌